Table of Contents
List of Tables
List of Figures

I. Key Findings

1. Companies Investing in Klebsiella pneumoniae Pipeline include
Number of Companies with Klebsiella pneumoniae projects in pre-clinical Development-
Number of Companies with Klebsiella pneumoniae projects in Clinical Development-
Klebsiella pneumoniae Pipeline Companies based in Americas
Klebsiella pneumoniae Pipeline Companies based in Europe
Klebsiella pneumoniae Pipeline Companies based in Asia Pacific
Klebsiella pneumoniae Pipeline Companies based in Rest of the World

2. Pipeline Candidates include
Klebsiella pneumoniae Pipeline Agents in pre- clinical/ Discovery stage of Development
Klebsiella pneumoniae Pipeline Agents in Clinical Development stage
Klebsiella pneumoniae Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Klebsiella pneumoniae Pipeline agents

II. Insights into Klebsiella pneumoniae Pipeline

1. Disease Overview
Introduction to Klebsiella pneumoniae
Symptoms and Causes of Klebsiella pneumoniae
Treatment or Prevention Options for Klebsiella pneumoniae
Other Details

2. Phase wise Pipeline Compounds
Klebsiella pneumoniae Pipeline- Pre- Clinical/ Discovery stage Drugs
Klebsiella pneumoniae Pipeline- Phase 1 stage Drugs
Klebsiella pneumoniae Pipeline- Phase 2 stage Drugs
Klebsiella pneumoniae Pipeline- Phase 3 stage Drugs
Klebsiella pneumoniae Pipeline- Pre-Registration stage Drugs

3. Company wise Klebsiella pneumoniae Pipeline Compounds

4. Klebsiella pneumoniae Pipeline by Mechanism of Action

III. Klebsiella pneumoniae Pipeline Compound Details
- Small Molecules for K.pneumoniae Infections
- GYR12
- BioPhage therapeutics
- ATI-1503
- ASN300
- C3J-EP-XX
- Gram Negative Bacterial Infections
- Debio 1454
- EBX-004
- EVX-B4 VAP
- FPI-1465
- Small Molecules for Bacterial Infections
- Lpxc
- CTIX1278
- LCB18-0055
- RX-04
- RX-P873
- NOSO-502
- OTP-602
- PT4
- cefiderocol
- SPR741
- Klebsiella pneumoniae vaccine(Syntiron)
- TP-6076
- bacterial infection therapeutics
- Klebsiella pneumoniae vaccine
- VRP-001

Drug Details

1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/ License Partner
Orphan Drug / Fast Track/ Designation
Development Phase

2. Drug Overview

3. Mechanism of Action

4. Current Status

5. Clinical Trial Details

IV. Klebsiella pneumoniae Pipeline Company Briefs
- ABAC Therapeutics SA
- Abgentis Ltd
- AmpliPhi Biosciences Corp
- Appili Therapeutics Inc
- Arsanis Inc
- C3J Therapeutics Inc
- ContraFect Corporation
- Debiopharm International SA
- EnBiotix Inc
- Evaxion Biotech ApS
- Fedora Pharmaceuticals Inc
- Forge Therapeutics Inc
- Innovation Pharmaceuticals Inc
- LegoChem Biosciences Inc
- Melinta Therapeutics Inc
- Nosopharm SAS
- Oryn Therapeutics LLC
- Phico Therapeutics Ltd
- Shionogi & Co Ltd
- Spero Therapeutics Inc
- Syntiron LLC
- Tetraphase Pharmaceuticals Inc
- Vaxdyn SL
- Vaxxilon AG

V. Latest News and Developments in Global Klebsiella pneumoniae Pipeline Market
VI. Appendix

1. Publisher's Expertise

2. Research Methodology

3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability

Companies Mentioned:
ABAC Therapeutics SA
Abgentis Ltd
AmpliPhi Biosciences Corp
Appili Therapeutics Inc
Arsanis Inc
C3J Therapeutics Inc
ContraFect Corporation
Debiopharm International SA
EnBiotix Inc
Evaxion Biotech ApS
Fedora Pharmaceuticals Inc
Forge Therapeutics Inc
Innovation Pharmaceuticals Inc
LegoChem Biosciences Inc
Melinta Therapeutics Inc
Nosopharm SAS
Oryn Therapeutics LLC
Phico Therapeutics Ltd
Shionogi & Co Ltd
Spero Therapeutics Inc
Syntiron LLC
Tetraphase Pharmaceuticals Inc
Vaxdyn SL
Vaxxilon AG